Salt Lake Life Science Angels

David J. Bearss, a co-founder with a background as a cancer biologist and serial entrepreneur, serves as the Managing Director most closely associated with the firm's investment posture. Brian K. Dunn and Craig W. Anderson also hold Managing Director roles and participate in diligence and syndication decisions. The group employs a distributed committee model where individual deals are championed by domain-expert members before the broader network is invited to participate.

Deal flow derives primarily from the University of Utah's translational-science pipeline, the Huntsman Cancer Institute, and Intermountain Healthcare's clinical networks. The group also sources opportunities via its managing directors' personal networks in biotech hubs — Bearss has longstanding ties to UK biotech clusters in Belfast and Edinburgh, which have produced cross-border syndications. The firm's member base of practicing physicians and former pharma executives further extends its sourcing reach into clinical-stage assets that institutional funds may not encounter at the seed stage.

SLLSA operates strictly as an angel network, not a blind-pool fund. Members evaluate and commit to individual deals on a deal-by-deal basis, with no pooled capital or committed-drawdown structure. This allows members to selectively participate only in opportunities within their scientific or clinical domains of expertise. The group does not charge a management fee; administrative costs are covered through membership dues and sponsor contributions.

The group targets seed and pre-Series A rounds, typically deploying between $250,000 and $1 million per syndicated round. These investments are positioned to bridge the gap between SBIR/STTR grants and a full institutional Series A led by coastal venture firms. SLLSA will, on occasion, participate in Series A extensions for portfolio companies that need a small bridge to reach a value-inflection milestone, but late-stage growth rounds are not part of the mandate.

SLLSA explicitly avoids pure software plays unless the software is a regulatory-cleared medical device (SaMD) or a component of a therapeutic platform. The group does not invest in consumer health, nutraceuticals, or lifestyle apps. Within life sciences, they remain agnostic to modality — the portfolio spans small molecules, biologics, peptides, and devices — but the common thread is a requirement that the asset be patent-protected and targeting a pathway to FDA or EMA clearance.

The Belfast and Shanghai offices operate as satellite syndication nodes rather than fully staffed investment offices. The Belfast operation, formalized in 2023 via a UK-registered co-investment vehicle, facilitates US member participation in Northern Ireland-based life-science seed rounds structured under Innovate UK frameworks. The Shanghai presence serves as a partner-development and regulatory-pathway bridge for portfolio companies seeking Chinese NMPA clearance or Asia-Pacific strategic partners.

SLLSA prefers to co-invest alongside named institutional leads — typically firms like Arch Venture Partners, Flagship Pioneering, or venBio — rather than leading rounds independently. The group's check size is intentionally calibrated to be non-threatening to a lead investor's allocation, allowing SLLSA to access competitive syndicates without demanding board seats or blocking rights. This 'friendly sidecar' posture has been central to the group's ability to get into oversubscribed biotech seed rounds.